New Agents Are Coming, and So Is the Resistance

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat, necessitating urgent action to curb the spread of resistant pathogens.
• Declining investment in novel antimicrobial development due to narrow profit margins has led to a decrease in new antibiotic production.
• The United States Centers for Disease Control and Prevention (CDC) advocates for antimicrobial stewardship, emphasizing reporting and documentation of antimicrobial use and resistance.

Purpose of the Study:

• To review current and future global health challenges posed by antimicrobial resistance.
• To discuss the new Infectious Diseases Society of America (IDSA) guidelines for treating resistant Gram-negative pathogens.
• To highlight newly approved or anticipated antimicrobial agents, their target pathogens, and clinical applications.

Main Methods:

• Literature review of global health challenges related to antimicrobial resistance.
• Analysis of new Infectious Diseases Society of America (IDSA) guidelines for resistant Gram-negative pathogens.
• Examination of new antimicrobial agents, including those nearing FDA approval, their coverage, and potential clinical utility.

Main Results:

• Antimicrobial resistance presents complex global health challenges requiring multifaceted solutions.
• New guidelines and emerging antimicrobial agents offer potential strategies to combat resistant Gram-negative pathogens.
• Addressing economic factors in antimicrobial drug discovery and improving healthcare reimbursement are crucial.

Conclusions:

• Urgent action is needed to improve antimicrobial drug discovery and healthcare reimbursement to avert a post-antibiotic era.
• The discussed guidelines and novel agents represent critical advancements in managing resistant infections.
• Effective antimicrobial stewardship and the development of new treatments are vital for global health security.